Scholar Rock’s (SRRK) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Scholar Rock (NASDAQ:SRRK) in a research note published on Tuesday,Benzinga reports. They currently have a $58.00 price target on the stock. HC Wainwright also issued estimates for Scholar Rock’s FY2030 earnings at $1.26 EPS.

A number of other equities research analysts have also issued reports on the company. BMO Capital Markets reiterated an “outperform” rating and issued a $50.00 target price on shares of Scholar Rock in a research note on Friday, November 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research note on Thursday, January 22nd. JPMorgan Chase & Co. boosted their target price on shares of Scholar Rock from $46.00 to $47.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Finally, Wolfe Research began coverage on shares of Scholar Rock in a report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 price target for the company. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $54.14.

Scholar Rock Stock Performance

NASDAQ:SRRK opened at $46.15 on Tuesday. The firm’s fifty day simple moving average is $45.33 and its 200 day simple moving average is $39.19. The company has a current ratio of 6.95, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock has a twelve month low of $22.71 and a twelve month high of $49.82. The firm has a market capitalization of $5.30 billion, a price-to-earnings ratio of -13.45 and a beta of 0.70.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.10. During the same period last year, the company earned ($0.64) earnings per share. As a group, equities research analysts expect that Scholar Rock will post -2.42 earnings per share for the current fiscal year.

Insider Activity at Scholar Rock

In other news, COO Keith Woods sold 16,746 shares of the stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $715,054.20. Following the sale, the chief operating officer directly owned 583,254 shares in the company, valued at approximately $24,904,945.80. This represents a 2.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Vikas Sinha sold 16,755 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total value of $715,438.50. Following the completion of the sale, the chief financial officer directly owned 583,245 shares in the company, valued at approximately $24,904,561.50. This trade represents a 2.79% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 208,470 shares of company stock valued at $9,201,778. 13.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Scholar Rock

Several hedge funds and other institutional investors have recently modified their holdings of SRRK. IFP Advisors Inc increased its holdings in shares of Scholar Rock by 294.1% in the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after acquiring an additional 450 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in Scholar Rock during the 4th quarter valued at about $30,000. Summit Securities Group LLC bought a new position in Scholar Rock in the 4th quarter worth about $31,000. Ramirez Asset Management Inc. bought a new position in Scholar Rock in the 3rd quarter worth about $37,000. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after purchasing an additional 525 shares during the period. Institutional investors and hedge funds own 91.08% of the company’s stock.

More Scholar Rock News

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Major analysts raised ratings and targets — BMO bumped its target to $70 (Outperform), Citigroup raised its target to $58 (Buy) and Piper Sandler lifted its target to $58 (Overweight), signaling fresh upside expectations. Analyst Price Target Raises Piper Sandler Note
• Positive Sentiment: HC Wainwright raised its FY2030 EPS forecast to $1.26 (from $1.07) and reiterated a Buy rating with a $58 price target — a bullish long‑term earnings view that contrasts with current street estimates. HC Wainwright Upgrade
• Positive Sentiment: Scholar Rock reported progress on apitegromab: management outlined a 2026 BLA resubmission plan and commercial launch preparations following favorable interactions with the FDA — this is the primary operational catalyst for upside if approval and launch proceed. FDA / BLA Progress
• Neutral Sentiment: Q4 2025 results marginally beat expectations (EPS about -$0.88 vs. consensus ~ -$0.8825), showing stability but not a strong inflection in near‑term profitability. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Street consensus still expects a negative EPS for the current fiscal year (≈ -$2.42), underlining that near‑term earnings and cash‑flow risk remain until apitegromab is approved and commercialized. Consensus EPS Context

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).